Year-End Report

WINSTON TAYLOR LLP (FORMERLY KNOWN AS WINSTON & STRAWN LLP) for BARR LABORATORIES INC

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline

LobbyistCovered position, as disclosed
WESLEY BIZZELL —
CHARLES L KINNEY N/A
JOHN D MCMICKLE N/A
JOHN A WAITS N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 316 (110th), H.R. 1956 (110th), H.R. 3161 (110th), H.R. 806 (110th), H.R. 1908 (110th), S. 1695 (110th), S. 1082 (110th), S. 1145 (110th), S. 1859 (110th), H.R. 2764 (110th), H.R. 3580 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.